Anti-TSLP monoclonal antibodies, antigen-binding fragments thereof and uses thereof

Anti-TSLP monoclonal antibodies address the challenge of severe asthma by inhibiting TSLP receptor interaction, reducing inflammation, and improving asthma control, particularly in non-T2-induced cases, with high affinity and stability for therapeutic applications.

JP2024541557AActive Publication Date: 2024-11-08BEIJING DONGFANG BIOTECH CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024531546
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-02
Filing Date
2022-11-18
Publication Date
2024-11-08
Estimated Expiration
2042-11-18

Smart Images

  • Figure 2024541557000001_ABST
    Figure 2024541557000001_ABST
Patent Text Reader

Abstract

The present invention provides an anti-TSLP monoclonal antibody, an antigen-binding fragment thereof, and uses thereof. Such an antibody has high affinity for the TSLP antigen and can effectively inhibit the binding of the TSLP antigen to its receptor complex, thereby preventing the release of pro-inflammatory cellular factors from immune cells targeted by TSLP, and can improve asthma control while preventing asthma attacks; the monoclonal antibody molecule screened in the present invention further has high thermal stability and good safety, and the present invention can be used to treat asthma, chronic obstructive pulmonary disease, chronic eosinophilic pneumonia, idiopathic pulmonary fibrosis, and allergic dermatitis; asthma includes severe asthma, eosinophilic or non-eosinophilic asthma, and hypoeosinophilic asthma.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [CROSS-CIRCUMSTANCES OF RELATED APPLICATIONS] This application claims priority to Chinese application No. 202111461974.6 filed on December 02, 2021, the contents of which are incorporated herein by reference.

[0002] The present invention relates to the technical field of biomedicine, and in particular to an anti-TSLP monoclonal antibody, an antigen-binding fragment thereof, and uses thereof. [Background technology]

[0003] Asthma is currently one of the most common chronic diseases in the world. The incidence rate of asthma is about 4.3%. There are about 300 million asthma patients worldwide. The prevalence rate of asthma varies from 1% to 18% in each country, and 10% to 20% of severe asthma patients are difficult to control with current treatments, and these patients consume 50% to 60% of asthma medical expenses. Due to economic limitations, many patients in a wide range of developing countries cannot receive effective diagnosis and treatment, including China. On June 21, 2019, the internationally authoritative medical journal Liuye Dao published another important result of the "China Adult Lung Health Study" (CPHStudy), a large-scale population study completed by Chinese scholars, revealing the prevalence of asthma in China, revealing that the prevalence rate of asthma in the population aged 20 and over in China is 4.2%, and the number of patients reaches 45.7 million. In China, asthma has become one of the major public health and medical problems that must be seriously confronted and solved. According to the Chinese Guidelines for the Prevention and Treatment of Bronchial Asthma, more than 70% of asthma patients in China are still in a state of poor control, and the incidence of emergency visits and hospitalizations due to asthma attacks in patients during the year is as high as 27% and 23%, respectively. Poor asthma control has a serious impact on the quality of life of patients.

[0004] Asthma is a chronic inflammatory disease of the airway involving various inflammatory cells and mediators. Such chronic inflammation is associated with high airway reactivity, and clinical manifestations include repeated asthma attacks, shortness of breath, chest distress, coughing, etc., and in many cases, attacks and aggravation occur at night and / or early in the morning, and many patients can relieve it themselves or receive treatment; pathologically, it is manifested as chronic inflammatory changes in the airway and remodeling of the airway, the latter including thickening of the airway wall, deposition of matrix and collagen, subepithelial fibrosis, proliferation and hypertrophy of smooth muscle, proliferation of myofibroblasts, and metaplasia and proliferation of mucous glands and goblet cells, etc., which poses great difficulties in treatment. Up to now, there are many types of asthma drugs on the market worldwide, most of which are chemical drugs. With the continuous development of biological drugs, the development of biological drugs for asthma is gradually attracting attention.

[0005] T2-induced (T2-high) asthma is found in more than two-thirds of severe asthma patients. Its typical feature is elevated levels of T2-type inflammatory biomarkers. Identification of diagnostic and predictive biomarkers (including blood eosinophils, serum IgE, exhaled nitric oxide (FeNO), Periostin, etc.) has revolutionized the field of targeted treatment of severe asthma. Monoclonal antibodies targeting Th2-induced inflammation are generally safe in adult moderate to severe asthma patients. The remaining approximately one-third of severe asthma patients do not have the characteristics of an activated T2 inflammatory pathway, and non-T2-induced disease in these patients cannot be controlled by treating them with clinical standard guidelines. Research on non-type 2 asthma is unclear, and further studies are needed to determine biomarkers to guide targeted treatment of different forms of non-type 2 asthma.

[0006] Thymic stromal lymphopoietin (TSLP) is an epithelial cell factor produced in response to proinflammatory stimuli (e.g., intrapulmonary allergens, viruses, and other pathogens) and has the effect of enhancing thymocyte proliferation. TSLP induces the release of downstream T2 cell factors, including IL-4, IL-5, and IL-13, which cause inflammation and asthma symptoms. TSLP can also activate multiple types of cells that participate in non-T2-induced inflammation. Thus, the early upstream action of TSLP in the inflammatory cascade has already identified it as a potential target in a wide range of asthma patients.

[0007] TSLP also regulates immunity by activating immature DCs, lymphocytes, hypertrophic cells, basophils, and eosinophils. TSLP initiates intracellular signaling by forming a complex with its specific receptor TSLPR and the common receptor IL-7Rα. TSLP first binds to TSLPR with high affinity and then forms a ternary complex with the extracellular domain of IL-7Rα. The two opposing faces of TSLP interact with TSLPR and IL-7Rα, respectively. STAT5 activation is a necessary signal for TSLP-mediated Th2 responses. Anti-TSLP humanized monoclonal antibodies can specifically bind to human TSLP and block its interaction with the receptor complex, thereby preventing the release of proinflammatory cellular factors from TSLP-targeted immune cells, thus improving asthma control while preventing asthma attacks.

[0008] Currently, Tezepelumab (also known as AMG157) from AstraZeneca and its partner Amgen is the first monoclonal antibody drug targeting TSLP, but it has not yet been launched. Clinical studies have shown that anti-TSLP humanized monoclonal antibodies act early upstream of the inflammatory cascade reaction and can be applied to a wide range of severe patients with uncontrolled asthma, including those with non-T2-induced asthma, and a proof-of-concept challenge study of inhaled allergens deployed in mild and atopic asthma patients has demonstrated that it can reduce the levels of T2-type inflammatory biomarkers while suppressing early and late asthma responses. Given the importance of TSLP-targeted drugs in asthma treatment, it is necessary to develop monoclonal antibody drugs that can be used as a monotherapy or adjunctive treatment for asthma to meet the demand of asthma patients both at home and abroad. Summary of the Invention [Problem to be solved by the invention]

[0009] In order to meet the market demand, in the present invention, anti-TSLP monoclonal antibodies that can specifically bind to TSLP and have high biological activity, antigen-binding fragments thereof, and uses thereof are obtained by screening immune libraries. [Means for solving the problem]

[0010] The specific technical solutions of the present invention are as follows:

[0011] The present invention provides an anti-TSLP monoclonal antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region containing three heavy chain complementarity determining regions represented by HCDR1, HCDR2, and HCDR3, respectively, and a light chain variable region containing three light chain complementarity determining regions represented by LCDR1, LCDR2, and LCDR3, respectively, and the monoclonal antibody or the antigen-binding fragment thereof is AI: the heavy chain complementarity determining region HCDR1 comprises an amino acid sequence as shown in SEQ ID NO:1, the heavy chain complementarity determining region HCDR2 comprises an amino acid sequence as shown in SEQ ID NO:2, the heavy chain complementarity determining region HCDR3 comprises an amino acid sequence as shown in SEQ ID NO:3, the light chain complementarity determining region LCDR1 comprises an amino acid sequence as shown in SEQ ID NO:4, the light chain complementarity determining region LCDR2 comprises an amino acid sequence as shown in SEQ ID NO:5, and the light chain complementarity determining region LCDR3 comprises an amino acid sequence as shown in SEQ ID NO:6; A-II: the heavy chain complementarity determining region HCDR1 comprises an amino acid sequence as shown in SEQ ID NO:7, the heavy chain complementarity determining region HCDR2 comprises an amino acid sequence as shown in SEQ ID NO:8, the heavy chain complementarity determining region HCDR3 comprises an amino acid sequence as shown in SEQ ID NO:9, the light chain complementarity determining region LCDR1 comprises an amino acid sequence as shown in SEQ ID NO:4, the light chain complementarity determining region LCDR2 comprises an amino acid sequence as shown in SEQ ID NO:10, and the light chain complementarity determining region LCDR3 comprises an amino acid sequence as shown in SEQ ID NO:6; A-III: the heavy chain complementarity determining region HCDR1 comprises an amino acid sequence as shown in SEQ ID NO:1, the heavy chain complementarity determining region HCDR2 comprises an amino acid sequence as shown in SEQ ID NO:11, the heavy chain complementarity determining region HCDR3 comprises an amino acid sequence as shown in SEQ ID NO:3, the light chain complementarity determining region LCDR1 comprises an amino acid sequence as shown in SEQ ID NO:12, the light chain complementarity determining region LCDR2 comprises an amino acid sequence as shown in SEQ ID NO:13, and the light chain complementarity determining region LCDR3 comprises an amino acid sequence as shown in SEQ ID NO:14; and A-IV: The present invention provides an anti-TSLP monoclonal antibody or an antigen-binding fragment thereof, the anti-TSLP monoclonal antibody being any one of the following: the heavy chain complementarity determining region HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1; the heavy chain complementarity determining region HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 11; the heavy chain complementarity determining region HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 3; the light chain complementarity determining region LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 12; the light chain complementarity determining region LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 15; and the light chain complementarity determining region LCDR3 comprises the amino acid sequence shown in SEQ ID NO: 16.

[0012] In the present invention, the above four types of monoclonal antibody molecules that can bind to the TSLP antigen with high affinity are obtained by screening an immune library. The antibody molecules have good binding activity, which prevents interaction with the receptor complex and further prevents the release of proinflammatory cellular factors from immune cells targeted by TSLP, preventing asthma attacks and improving asthma control. The monoclonal antibody molecules screened in the present invention also have relatively high thermal stability, which meets the conditions for drug production.

[0013] Furthermore, the monoclonal antibody or antigen-binding fragment thereof is a mouse-derived antibody molecule, and the mouse-derived antibody molecule is MA-I: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:17 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:18; MA-II: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:19 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:20; MA-III: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:21 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:22; and MA-IV: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:23, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:24; Preferably, the mouse-derived antibody molecule is MA-I.

[0014] In the present invention, mice are immunized with TSLP antigen, the immunization method is optimized, a phage display library is constructed, and the mouse-derived antibody molecules with high affinity, good activity and stability are screened. After verification by a large number of cell-level experiments, it is found that MA-I has higher biological activity than the other three mouse-derived antibody molecules. Therefore, in the present invention, MA-I is the preferred choice.

[0015] Furthermore, the mouse-derived antibody molecule further comprises a mouse-derived antibody heavy chain constant region selected from mouse IgG1, IgG2a, IgG2b, or IgG3 heavy chain constant regions, and a mouse-derived antibody light chain constant region; provided that the amino acid sequence of the IgG1 heavy chain constant region is as shown in SEQ ID NO: 26, the amino acid sequence of the IgG2a heavy chain constant region is as shown in SEQ ID NO: 27, the amino acid sequence of the IgG2b heavy chain constant region is as shown in SEQ ID NO: 28, and the amino acid sequence of the IgG3 heavy chain constant region is as shown in SEQ ID NO: 29; and the mouse-derived antibody light chain constant region is selected from mouse C k a light chain constant region of the type Ib-IIb type, the amino acid sequence of which is as set forth in SEQ ID NO:25; Preferably, the mouse-derived antibody molecule comprises a mouse IgG1-type heavy chain constant region and a mouse C k and a light chain constant region of the type

[0016] Furthermore, the monoclonal antibody or antigen-binding fragment thereof is a chimeric antibody molecule, and the chimeric antibody molecule comprises a heavy chain variable region of the mouse-derived antibody molecule, a light chain variable region of the mouse-derived antibody molecule, and a human-derived antibody constant region.

[0017] The chimeric antibody molecule comprises the variable region sequence of a mouse-derived antibody molecule and a human-derived antibody constant region, and the design of the chimeric antibody molecule is used to verify that the specific function of the CDR is not altered after the constant region is humanized in the present invention, providing a basis for further research and development in the study of humanized antibody molecules.

[0018] Furthermore, the monoclonal antibody or antigen-binding fragment thereof is a humanized antibody molecule, and the humanized antibody molecule is HA-I: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:34 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:35; HA-II: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:34 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:36; HA-III: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:37 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:38; and HA-IV: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:37, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:36; Preferably, the humanized antibody molecule is HA-I.

[0019] In the present invention, mouse-derived antibody molecules are humanized and then screened for humanized antibody molecules. As a result of in vitro and in vivo experiments, it is found that HA-I has the highest biological activity and the most significant pharmacological effect among the four humanized antibody molecules proposed in the present invention. Therefore, HA-I is preferred in the present invention.

[0020] Furthermore, the humanized antibody molecule further comprises an antibody constant region of human origin.

[0021] Furthermore, the humanized antibody molecule is a full length antibody or an antibody fragment, and the humanized antibody molecule comprises one or a combination of several of Fab, F(ab)2, Fv, or ScFv.

[0022] Furthermore, the human-derived antibody constant region comprises a human-derived antibody heavy chain constant region selected from human IgG1, IgG2, or IgG4 heavy chain constant regions, and a human-derived antibody light chain constant region, the amino acid sequence of the IgG1 heavy chain constant region being as shown in SEQ ID NO: 30, the amino acid sequence of the IgG2 heavy chain constant region being as shown in SEQ ID NO: 31, and the amino acid sequence of the IgG4 heavy chain constant region being as shown in SEQ ID NO: 32, and the human-derived antibody light chain constant region being selected from human C k a light chain constant region of the type Ib-IIb type, the amino acid sequence of which is as set forth in SEQ ID NO:33; Preferably, the human-derived antibody constant region is a combination of a human IgG1 heavy chain constant region and a human C k and a light chain constant region of the type

[0023] The present invention further proposes a protein comprising the above-mentioned anti-TSLP monoclonal antibody or an antigen-binding fragment thereof.

[0024] The present invention further provides a polynucleotide molecule encoding the above-mentioned anti-TSLP monoclonal antibody or an antigen-binding fragment thereof.

[0025] The present invention further provides a recombinant DNA expression vector comprising the above-described polynucleotide molecule.

[0026] The present invention further provides a host cell transfected with the recombinant DNA expression vector described above, said host cell comprising a prokaryotic cell, a yeast cell, an insect cell or a mammalian cell; Preferably, said host cell is a mammalian cell, said mammalian cell being proposed to be a HEK293 cell, a CHO cell or an NS0 cell.

[0027] The present invention further proposes a drug comprising the above-mentioned anti-TSLP monoclonal antibody or an antigen-binding fragment thereof.

[0028] The present invention further relates to use of the anti-TSLP monoclonal antibody or antigen-binding fragment thereof in the manufacture of a therapeutic agent for immune diseases or cancer; Preferably, said immune-mediated disease comprises asthma, chronic obstructive pulmonary disease, chronic eosinophilic pneumonia, idiopathic pulmonary fibrosis, allergic dermatitis; said asthma comprises severe asthma, eosinophilic or non-eosinophilic asthma, hypoeosinophilic asthma; Preferably, the cancer comprises pancreatic cancer, non-small cell lung cancer, melanoma, prostate cancer, renal cancer, colorectal cancer or breast cancer.

[0029] The present invention further provides a method for treating or preventing a TSLP-mediated disease, comprising administering to an individual in need thereof a therapeutically effective amount of an anti-TSLP monoclonal antibody as described above, wherein the disease comprises an immune disease or cancer; The immune disorders include asthma, chronic obstructive pulmonary disease, chronic eosinophilic pneumonia, idiopathic pulmonary fibrosis, and allergic dermatitis; the asthma includes severe asthma, eosinophilic or non-eosinophilic asthma, and hypoeosinophilic asthma; The method provides that the cancer comprises pancreatic cancer, non-small cell lung cancer, melanoma, prostate cancer, renal cancer, colorectal cancer, or breast cancer. Effect of the Invention

[0030] The beneficial effects of the present invention include at least the following: the anti-TSLP monoclonal antibody or antigen-binding fragment thereof provided by the present invention has high affinity to the TSLP antigen, effectively inhibits the binding of the TSLP antigen to its receptor complex, and can block the release of pro-inflammatory cellular factors from immune cells targeted by TSLP, thereby preventing asthma attacks and improving asthma control. In addition, the monoclonal antibody molecule screened by the present invention also has high thermal stability and good safety. The anti-TSLP monoclonal antibody or antigen-binding fragment thereof screened by the present invention can be used to treat immune diseases or cancer. The immune diseases include, but are not limited to, asthma, chronic obstructive pulmonary disease, chronic eosinophilic pneumonia, idiopathic pulmonary fibrosis, and allergic dermatitis; the asthma includes, but is not limited to, severe asthma, eosinophilic or non-eosinophilic asthma, and hypoeosinophilic asthma; the cancer includes, but is not limited to, pancreatic cancer, non-small cell lung cancer, melanoma, prostate cancer, renal cancer, colorectal cancer, and breast cancer. [Brief description of the drawings]

[0031] [Figure 1] 1 shows a plasmid profile of vector pScFv-Disb-HS in Example 2 of the present invention. [Diagram 2] FIG. 11 is a diagram comparing the relative affinities of anti-TSLP phage monoclonal antibodies by serial dilution ELISA in Example 3 of the present invention. [Diagram 3] 1 shows a profile of vector pTSE in Example 5 of the present invention. [Figure 4] FIG. 13 is a denaturing polyacrylamide gel electrophoresis diagram of mouse-derived antibody molecules in Example 5 of the present invention. [Diagram 5] FIG. 11 is a diagram comparing the binding ability of mouse-derived antibodies and TSLP in Example 6 of the present invention. [Figure 6] FIG. 13 is a comparative diagram of a competitive inhibition experiment between a mouse-derived antibody and the TSLP receptor protein CRLF2 in Example 7 of the present invention. [Figure 7]FIG. 13 is a denaturing polyacrylamide gel electrophoresis diagram of the humanized antibody molecule in Example 12 of the present invention. [Figure 8] FIG. 13 is a diagram comparing the binding ability of the humanized antibody molecule in Example 15 of the present invention with TSLP. [Figure 9] FIG. 13 is a comparative diagram of a competitive inhibition experiment between a humanized antibody and a control antibody in Example 16 of the present invention. [Figure 10] FIG. 13 is a diagram showing a cross-binding experiment between the humanized antibody in Example 17 of the present invention and TSLP from different species. [Figure 11] FIG. 13 is a comparative diagram showing an experiment on inhibition of the binding of TSLP to cell surface receptors by anti-TSLP monoclonal antibodies in Example 18 of the present invention. [Figure 12] FIG. 13 is a comparative diagram showing the detection of biological activity (reporter gene method) of anti-TSLP monoclonal antibodies in Example 19 of the present invention. [Figure 13] FIG. 13 is a comparative diagram showing inhibition of chemokine release from TSLP-induced mDC cells by anti-TSLP monoclonal antibodies in Example 20 of the present invention. [Figure 14] FIG. 13 is a diagram evaluating the thermal stability of anti-TSLP monoclonal antibody HA-1 in Example 21 of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] In order to make the present invention more readily understandable, before describing the examples, some technical and scientific terms in the present invention are explained below.

[0033] The term "antibody" as used herein includes whole antibodies and any one of the antigen-binding fragments thereof. Antibodies include murine, humanized, bispecific or chimeric antibodies. Antibodies may be Fab, F(ab)2, Fv or ScFv (single chain antibodies). Antibodies may be naturally occurring or altered (e.g., mutation, deletion, substitution, etc.).

[0034] As used herein, the terms "variable region" and "constant region" refer to the sequence regions adjacent to the N-terminus of the heavy and light chains of an antibody, which are variable regions (V regions). The remaining amino acid sequences adjacent to the C-terminus are relatively stable and are constant regions (C regions). The variable regions contain three complementarity determining regions (CDRs) and four framework regions (FRs). Each light chain variable region and heavy chain variable region is composed of three CDR regions and four FR regions. The three CDR regions of the heavy chain are designated HCDR1, HCDR2, and HCDR3, respectively. The three CDR regions of the light chain are designated LCDR1, LCDR2, and LCDR3, respectively.

[0035] As used herein, the term "mouse-derived antibody molecule" is derived from an antibody obtained after immunizing a mouse with a TSLP antigen.

[0036] The term "chimeric antibody molecule" as used herein refers to an antibody in which the variable region of a mouse-derived antibody is fused with the constant region of a human-derived antibody, and can reduce the immune response reaction induced by mouse-derived antibodies in the human body. A chimeric antibody is formed by inserting the light and heavy chain variable region genes of a mouse-derived single antibody into an expression vector containing a human antibody constant region by DNA recombination technology, and in the antibody molecule expressed in this way, the variable regions of the light and heavy chains are of mouse origin, while the constant region is of human origin, and nearly two-thirds of the entire antibody molecule is of human origin. The antibody produced in this way reduces the immunogenicity of mouse-derived antibodies and at the same time retains the ability of the parent antibody to specifically bind to an antigen.

[0037] As used herein, the term "humanized antibody molecule" refers to an antibody molecule in which the CDRs of a mouse-derived antibody are grafted into the variable region of a human-derived antibody in place of the CDRs of a human-derived antibody, thereby allowing the human antibody to acquire the antigen-binding specificity of the mouse-derived antibody and at the same time reducing its heterogeneity.

[0038] The term "CHO ​​cells" refers to Chinese hamster ovary cells. The term "HEK293 cells" refers to human embryonic kidney 293 cells. The term "NS0 cells" refers to mouse NS0 thymoma cells.

[0039] The present invention will now be described in more detail with reference to the following examples.

[0040] Example 1 Example 1 of the present invention provides an anti-TSLP monoclonal antibody or an antigen-binding fragment thereof. Specifically, the antibody comprises a heavy chain variable region containing three heavy chain complementarity determining regions represented by HCDR1, HCDR2, and HCDR3, respectively, and a light chain variable region containing three light chain complementarity determining regions represented by LCDR1, LCDR2, and LCDR3, respectively. The monoclonal antibody or antigen-binding fragment thereof is any one selected from the following. The following CDRs are determined based on the Kabat numbering system.

[0041] [Table 1]

[0042] Example 2: Screening of mouse-derived antibody molecules In the present invention, mice are immunized with TSLP antigen, the immunization method is optimized, a phage display library is constructed, and an antigen site screening method is established. The specific construction and screening of the phage display library are as follows:

[0043] Step 1: Immunize mice with TSLP antigen. 1. Experimental Animals Type and breed: BALB / c, female, mouse; Weight: 18-20g; Experimental animals provided by Beijing Huafukang Bio-Technology Co., Ltd. 2. Immunization: Mice were immunized with human TSLP (a synthetic gene from Nanjing Jinsirui Biotechnology Co., Ltd., which was expressed and purified using a vector constructed by our company) as an immunizing antigen.

[0044] Step 2: Construct a phage antibody library. High titer mouse spleen cells are taken, and total RNA in the mouse spleen cells is extracted using Trizol reagent (purchased from Ambion, product code: 15596026), and RT-PCR is performed to obtain cDNA. Using the cDNA as a template, PCR amplification is performed using degenerate primers (reference for the degenerate primers used: Journal of Immunological Methods 233 (2000) 167-177). This results in a heavy chain variable region gene library (VH) and a light chain variable region gene library (VL) of immunized mouse antibodies. Double enzyme digestion is performed for each of the light and heavy chains, and the pScFv-Disb-HS-VH-VL gene library is constructed by connecting the double enzyme digested vectors in the same stepwise manner. The pscFv-Disb-HS vector is used to construct and express the phage single chain antibody library after modifying the vector pComb3 (purchased from China Plasmid Vector Bacteria Cell Line Gene Preservation Center) by a series of gene cloning methods. The modified vector is named PscFv-Disb-HS vector, and its plasmid profile is shown in Figure 1. Furthermore, a mouse immune phage antibody library based on this vector is constructed.

[0045] Step 3: TSLP is used as an antigen to coat the immunotube, and the amount of antigen coated is 5 μg / 500 μl / tube, and the tube is coated overnight at 4°C. Then, the immunotube and the immune phage antibody library are respectively sealed with 4% skim milk powder / PBST, and the tube is sealed at room temperature for 1 h. The sealed immune phage antibody library is placed in the immunotube to perform antigen-antibody binding, and the amount of phage added is about 10 9 ~10 12After reacting at room temperature for 1 hour, unbound phages are removed with PBST-PBS and eluted with 0.1M Glycine-HCl, pH 2.2. Finally, the eluted phage-antibody solution is neutralized to about pH 7.0 with 1.5M Tris-HCl, pH 8.8.

[0046] Step 4: Infect 10 ml of TG1 bacteria solution grown to logarithmic phase with the neutralized phages and leave in a 37°C incubator for 30 min. Take a part of the bacteria solution, serially dilute it, coat it on a 2YTAG plate, and calculate the amount of phage produced. Centrifuge the remaining bacteria solution, discard the supernatant, resuspend the bacterial pellet in a small amount of medium, aspirate it, and coat it on a large 2YTAG plate for the next screening.

[0047] Step 5: The bacteria coated on the plate after the above infection are scraped off from the large plate and inoculated into 2YTAG liquid medium. After rocking until the plate reaches logarithmic phase, auxiliary phage M13KO7 is added for superinfection, and the plate is cultured overnight at 220 rpm at 28°C to produce phages. The phages are precipitated and purified with PEG-NaCl, and then prepared for the next round of screening. A total of one phage library enrichment screening is performed.

[0048] Step 6: Screening for TSLP phage single-chain antibody positive clones: After one round of screening, select well-isolated monoclonal colonies and inoculate them into 96-well deep well plates containing 2YTAG liquid medium. Incubate at 37°C and 220 rpm until they reach logarithmic growth phase. Approximately 10 cells per well were cultured. 10Add auxiliary phage M13KO7 and infect at 37°C for 30 min. Centrifuge at 4000 rpm for 15 min, discard the supernatant, resuspend the bacterial cell precipitate in 2YTAK, and incubate overnight at 28°C and 220 rpm. Centrifuge at 4000 rpm and 4°C for 15 min, then aspirate the amplified phage supernatant and perform ELISA measurement. Finally, screen four high affinity anti-TSLP mouse-derived antibody molecules, named MA-I, MA-II, MA-III, and MA-IV, respectively, and perform gene sequence measurement on the monoclonal antibodies obtained as above to determine the accurate antibody sequence. As a result of sequence measurement, the four monoclonal antibody sequences screened as above are as follows.

[0049] [Table 2]

[0050] in particular, SEQ ID NO: 17 (amino acid sequence of the heavy chain variable region of MA-I): [ka] SEQ ID NO: 18 (amino acid sequence of the light chain variable region of MA-I): [ka] SEQ ID NO:19 (amino acid sequence of the heavy chain variable region of MA-II): [ka] SEQ ID NO:20 (amino acid sequence of the light chain variable region of MA-II): [ka] SEQ ID NO:21 (amino acid sequence of the heavy chain variable region of MA-III): [ka] SEQ ID NO:22 (amino acid sequence of the light chain variable region of MA-III): [ka] SEQ ID NO: 23 (amino acid sequence of the heavy chain variable region of MA-IV): [ka] SEQ ID NO:24 (amino acid sequence of the light chain variable region of MA-IV): [ka]

[0051] In another aspect, the present invention further relates to an anti-TSLP monoclonal antibody or an antigen-binding fragment thereof as follows: Specifically, the antibody comprises a heavy chain variable region comprising three heavy chain complementarity determining regions represented by HCDR1, HCDR2, and HCDR3, respectively, and a light chain variable region comprising three light chain complementarity determining regions represented by LCDR1, LCDR2, and LCDR3, respectively, where HCDR1, HCDR2, and HCDR3 are HCDR1, HCDR2, and HCDR3 of the heavy chain variable region represented by SEQ ID NO: 17, 19, 21, or 23, respectively; and LCDR1, LCDR2, and LCDR3 are LCDR1, LCDR2, and LCDR3 of the light chain variable region represented by SEQ ID NO: 18, 20, 22, or 24, respectively. Those skilled in the art can determine the CDR sequences of heavy chain variable regions or light chain variable regions whose amino acid sequences are already known using commonly found numbering systems (e.g., Kabat, AbM, Chothia, Contact, or IMGT, etc.). When the Kabat numbering system is used to determine the CDRs, the CDR sequences of the heavy and light chain variable regions are as shown in Example 1.

[0052] Example 3: Comparison of the affinity of anti-TSLP phage monoclonal antibodies by serial dilution ELISA The four mouse-derived antibody molecules (MA-I, MA-II, MA-III, MA-IV) obtained in Example 2 are subjected to monoclonal phage display and purification, and then a serial dilution ELISA experiment of the phage is performed to identify the affinity. As a control antibody, the anti-TSLP monoclonal antibody Tezepelumab (also known as AMG157, patent application number CN201880026131.3, patent name is Treatment of Asthma with Anti-TSLP Antibody) from Amgen is selected. The specific method is as follows:

[0053] TSLP was coated with a carbonate buffer solution of pH 9.6, 100ng / well / 100μl, coated overnight at 4℃, washed three times with PBST, and each of the four phage monoclonal antibodies screened in Example 2 was serially diluted 4-fold with PBST, and the diluted samples were added at 100μl per well and allowed to stand at room temperature for 1h. The ELISA plate was washed with PBST, and HRP-anti-M13 (purchased from Bio-viewshine, product number: GE27-9421-01) monoclonal antibody diluted with PBST was added to the ELISA plate and allowed to stand at room temperature for 1h. The plate was developed with a TMB color development kit, developed at room temperature for 10 minutes, and then developed with 2M H2SO4. The values ​​were read at 450nm / 630nm on a microplate reader, and the corresponding EC 50 The value is calculated as follows:

[0054] [Table 3]

[0055] As shown by the above data and in Figure 2, all of the four different mouse-derived antibody molecules screened in Example 2 can bind to TSLP. However, compared with the other three mouse-derived antibody molecules and the control antibody, the monoclonal antibody MA-I provided by the present invention has a higher affinity for TSLP.

[0056] Example 4 Example 4 of the present invention further limits the following in addition to Example 2: the mouse-derived antibody molecule further comprises a mouse-derived antibody heavy chain constant region selected from mouse IgG1, IgG2a, IgG2b, or IgG3 heavy chain constant regions, and a mouse-derived antibody light chain constant region; provided that the amino acid sequence of the IgG1 heavy chain constant region is as shown in SEQ ID NO: 26, the amino acid sequence of the IgG2a heavy chain constant region is as shown in SEQ ID NO: 27, the amino acid sequence of the IgG2b heavy chain constant region is as shown in SEQ ID NO: 28, and the amino acid sequence of the IgG3 heavy chain constant region is as shown in SEQ ID NO: 29; the mouse-derived antibody light chain constant region is selected from mouse C k The light chain constant region of this type is as shown in SEQ ID NO: 25. The specific sequence is as follows:

[0057] SEQ ID NO: 25 (mouse C k Amino acid sequence of the light chain constant region of the type: [ka] SEQ ID NO: 26 (amino acid sequence of the heavy chain constant region of mouse IgG1 type): [ka] SEQ ID NO: 27 (amino acid sequence of the heavy chain constant region of mouse IgG2a type): [ka] SEQ ID NO: 28 (amino acid sequence of the heavy chain constant region of mouse IgG2b type): [ka] SEQ ID NO: 29 (amino acid sequence of the heavy chain constant region of mouse IgG3 type): [ka]

[0058] Example 5: Production of anti-TSLP mouse-derived antibody molecules In addition to Example 4, Example 5 of the present invention preferably limits the following: the mouse-derived antibody molecule is a heavy chain constant region of mouse IgG1 type (the amino acid sequence of which is shown in SEQ ID NO: 26) and a mouse C k and a light chain constant region of the same type (the amino acid sequence of which is shown in SEQ ID NO: 25). Specifically, the method for producing the antibody is as follows.

[0059] 1. The heavy chain VH and light chain VL coding genes of the four monoclonal antibodies obtained by screening in Example 2 were each cloned into the vector pTSE incorporating heavy and light chain constant region genes (as shown in FIG. 3), with the preferred heavy chain constant region being the mouse IgG1 type constant region (the amino acid sequence of which is shown in SEQ ID NO: 26), and the light chain constant region being the mouse-derived C k The structure of the vector pTSE is shown in FIG. 3 (for the process of producing the vector pTSE, see paragraph

[0019] on page 3 of the specification of CN103525868A).

[0060] 2. HEK293E cells (purchased from the Institute of Basic Medicine, Chinese Academy of Medical Sciences, product number: GNHu43) were instantly transfected to express the antibodies, and the four monoclonal antibodies were obtained by purifying them with a protein A affinity column using an AKTA instrument. At the same time, the protein concentration was measured using a BCA kit (purchased from Beijing Huitian Oriental Technology Co., Ltd., product number: BCA0020). Then, the protein size was identified using SDS-PAGE. As a result, as shown in Figure 4, from left to right, the bands are non-reduced MA-I, MA-II, MA-III, MA-IV, protein molecular weight markers, and reduced MA-I, MA-II, MA-III, MA-IV, mouse-derived anti-TSLP monoclonal antibodies, and the molecular weight size of each band is consistent with the theory.

[0061] Example 6: Binding experiment of mouse-derived antibodies with TSLP TSLP was coated with carbonate buffer, pH 9.6, at 100ng / well / 100μl, and coated overnight at 4℃. After washing five times with 300μl / well of PBST, 1% BSA-PBST was added and the plate was closed at 37℃ for 1h, and mouse antibodies MA-I, MA-II, MA-III, and MA-IV were added at different dilutions. The starting maximum concentration of the four antibodies was 1μg / ml, and each antibody was diluted 5-fold, making a total of 8 dilutions per antibody, and incubated at 37℃ for 1h. After washing five times with 300μl / well of PBST, Goat Anti-Mouse IgG-HRP (purchased from solarbio, product number: SE131) diluted 1:2000 with 1% BSA-PBST was added and incubated at 37℃ for 1h. Develop with TMB color development kit, 100 μl / well, 8 min at room temperature, and terminate with 2M H2SO4. Read at 450 nm / 630 nm on a microplate reader and obtain the corresponding EC 50 The value is calculated as follows:

[0062] [Table 4]

[0063] As shown in the above data and in Figure 5, all four different mouse-derived antibodies screened can bind to TSLP. Among these four mouse-derived antibody molecules, the EC of MA-I was 50 The value was the lowest, demonstrating that MA-I has a better binding ability with TSLP.

[0064] Example 7: Competitive inhibition experiment between mouse-derived antibodies and the TSLP receptor protein CRLF2 CRLF2-Fc was coated with carbonate buffer (pH 9.6) at 200ng / well / 100μl, and coated overnight at 4℃. After washing 5 times with 300μl / well of PBST, the plate was blocked with 1% BSA-PBST at 37℃ for 1h. TSLP-His diluted to 10μg / ml with 1% BSA-PBST was added at 50μl / well, and then mouse-derived antibodies MA-I, MA-II, MA-III, MA-IV and control antibodies were added at different dilutions at 50μl / well. The starting maximum concentration of the five antibodies was 400μg / ml, and each antibody was diluted 5-fold in a serial dilution, with a total of 8 dilutions for each antibody, and incubated at 37℃ for 2h. After washing five times with 300μl / well PBST, Anti-His-Tag Mouse-HRP (purchased from Beijing Kangwei Century Bio-Technology Co., Ltd., product code: CW0285) diluted 1:5000 with 2% BSA-PBST was added and incubated at 37℃ for 1h. Develop with TMB color development kit, 100μl / well at room temperature for 10min, and terminate with 2M H2SO4. Read the values ​​at 450nm / 630nm on a microplate reader and obtain the corresponding IC 50 The value is calculated as follows:

[0065] [Table 5]

[0066] As shown in the above data and in Figure 6, all of the four different mouse-derived antibodies screened can compete with the receptor protein CRLF2. Among the four mouse-derived antibody molecules provided by the present invention, the IC of MA-I was 50 This value was the lowest and was clearly superior to the control antibody, demonstrating that MA-I can effectively inhibit the binding of TSLP to the receptor protein CRLF2.

[0067] Example 8 Example 8 of the present invention further defines the following: the monoclonal antibody or antigen-binding fragment thereof is a chimeric antibody molecule. The chimeric antibody molecule comprises a heavy chain variable region of the mouse-derived antibody molecule in Example 2, a light chain variable region of the mouse-derived antibody molecule, and a human-derived antibody constant region. The human-derived antibody constant region comprises a human-derived antibody heavy chain constant region selected from human IgG1, IgG2, or IgG4 heavy chain constant regions, and a human-derived antibody light chain constant region. The amino acid sequence of the IgG1 type heavy chain constant region is as shown in SEQ ID NO: 30, the amino acid sequence of the IgG2 type heavy chain constant region is as shown in SEQ ID NO: 31, and the amino acid sequence of the IgG4 type heavy chain constant region is as shown in SEQ ID NO: 32. The human-derived antibody light chain constant region comprises a human C k and the amino acid sequence thereof is as shown in SEQ ID NO:33.

[0068] SEQ ID NO: 30 (human IgG1 type heavy chain constant region amino acid sequence): [ka] SEQ ID NO: 31 (amino acid sequence of the heavy chain constant region of human IgG2 type): [ka] SEQ ID NO: 32 (human IgG4 heavy chain constant region amino acid sequence): [ka] SEQ ID NO: 33 (human C k Amino acid sequence of the light chain constant region of the type: [ka]

[0069] Example 9: Production of chimeric antibody molecules Example 9 of the present invention further defines, in addition to Example 8, the following: the human-derived antibody constant region is a heavy chain constant region of human IgG1 type (the amino acid sequence of which is shown in SEQ ID NO: 30) and a human C kand a light chain constant region of the type Ib, the amino acid sequence of which is set forth in SEQ ID NO:33.

[0070] The specific manufacturing method is as follows. The heavy chain variable region VH (SEQ ID NO: 17) and light chain variable region VL genes (SEQ ID NO: 18) of the antibody molecule MA-I screened from the immune phage antibody library in Example 2 are cloned into the vector pTSE incorporating the heavy chain constant region and light chain constant region genes while leaving the mouse-derived sequences unchanged (as shown in FIG. 3). The heavy chain constant region is of human IgG1 type (amino acid sequence is as shown in SEQ ID NO: 30). The light chain constant region is of human C k The amino acid sequence is shown in SEQ ID NO: 33. HEK293E cells (purchased from the Institute of Basic Medicine, Chinese Academy of Medical Sciences, product code: GNHu43) were instantly transfected to express the antibody, and the chimeric antibody CA-I was obtained.

[0071] Example 10: Humanization of the mouse-derived antibody molecule MA-I First, the sequence of the mouse-derived antibody molecule MA-I in Example 2 is compared with the human antibody species database (v-base) to find a human antibody light and heavy chain species with high homology and set it as a candidate sequence. Then, the sequence of the CDR of the mouse-derived antibody molecule MA-I is transplanted into the human-derived candidate sequence to perform homology modeling. After that, the key frame amino acid residues that may play an important role in maintaining the CDR cyclic structure are calculated by three-dimensional structure simulation, and the restoration mutation of the humanized antibody is further designed. The light chain and heavy chain variable regions of the humanized antibody containing the designed restoration mutation are optimized and synthesized by Nanjing Jinsirui Biotechnology Co., Ltd., and then connected to an instantaneous expression vector, and the combination of the light and heavy chains obtained by humanization is analyzed to obtain the humanized antibody molecules HA-I, HA-II, HA-III, and HA-IV. The four monoclonal antibody sequences screened as above are as follows:

[0072] [Table 6]

[0073] in particular, SEQ ID NO: 34 (amino acid sequence of the heavy chain variable region of HA-I and HA-II): [ka] SEQ ID NO: 35 (amino acid sequence of the light chain variable region of HA-I): [ka] SEQ ID NO: 36 (amino acid sequence of the light chain variable region of HA-II and HA-IV): [ka] SEQ ID NO: 37 (amino acid sequence of the heavy chain variable region of HA-III and HA-IV): [ka] SEQ ID NO:38 (amino acid sequence of the light chain variable region of HA-III): [ka]

[0074] Example 11 Example 11 of the present invention further limits the following in addition to Example 10: the humanized antibody molecule further comprises a human-derived antibody constant region; the human-derived antibody constant region comprises a human-derived antibody heavy chain constant region selected from human IgG1, IgG2, or IgG4 heavy chain constant regions, and a human-derived antibody light chain constant region. The amino acid sequence of the IgG1 heavy chain constant region is as shown in SEQ ID NO: 30, the amino acid sequence of the IgG2 heavy chain constant region is as shown in SEQ ID NO: 31, and the amino acid sequence of the IgG4 heavy chain constant region is as shown in SEQ ID NO: 32. The human-derived antibody light chain constant region comprises a human C k and the amino acid sequence thereof is as shown in SEQ ID NO:33. The specific sequences of the constant regions of the above human-derived antibodies are the same as those in Example 8.

[0075] Example 12: Production of humanized antibody molecules Example 12 of the present invention further defines, in addition to Example 11, the following: the human-derived antibody constant region is a heavy chain constant region of human IgG1 type (the amino acid sequence of which is shown in SEQ ID NO: 30) and a human C k and a light chain constant region of the type Ib, the amino acid sequence of which is set forth in SEQ ID NO:33.

[0076] Each of the genes encoding the heavy chain VH and light chain VL of the four humanized antibody molecules obtained by humanization in Example 10 above is cloned into the vector pTSE incorporating the heavy chain constant region and light chain constant region genes (as shown in FIG. 3). The heavy chain constant region is human IgG1 type (amino acid sequence as shown in SEQ ID NO: 30), and the light chain constant region is C k The amino acid sequence is as shown in SEQ ID NO:33.

[0077] For each of the control antibody and humanized antibody molecules HA-I, HA-II, HA-III, and HA-IV, HEK293 cells (purchased from the Institute of Basic Medicine, Chinese Academy of Medical Sciences, product number: GNHu43) are instantly transfected to express the antibody. The monoclonal antibodies are obtained by purifying them with a protein A affinity column using an AKTA instrument, and at the same time, the protein concentration is measured using a BCA kit (purchased from Beijing Huitian Oriental Technology Co., Ltd., product number: BCA0020), and then the protein size is measured using SDS-PAGE. As a result, as shown in Figure 7, from left to right, the non-reduced protein molecular weights are HA-I, HA-II, HA-III, HA-IV, the chimeric antibody CA-I produced in Example 9, the control antibody, the non-reduced protein molecular weight marker 1, the reduced protein molecular weight marker 2, HA-I, HA-II, HA-III, HA-IV, the chimeric antibody CA-I, and the control antibody, and the molecular weight size of each band is consistent with the theory.

[0078] Example 13 In addition to the above examples, Example 13 of the present invention further limits that the humanized antibody molecule is a full-length antibody or an antibody fragment. The humanized antibody molecule includes one or more combinations of Fab, F(ab)2, Fv, or ScFv.

[0079] Example 14 In addition to the above embodiments, the fourteenth embodiment of the present invention further defines the following technical solutions.

[0080] Furthermore, the present invention provides a protein comprising an anti-TSLP monoclonal antibody or an antigen-binding fragment thereof defined in any one of the above embodiments.

[0081] The present invention further provides a polynucleotide molecule encoding an anti-TSLP monoclonal antibody or antigen-binding fragment thereof defined in any one of the above embodiments.

[0082] The present invention further provides a recombinant DNA expression vector comprising a polynucleotide molecule as defined above.

[0083] The present invention further provides a host cell transfected with a recombinant DNA expression vector as defined above, the host cell comprising a prokaryotic cell, a yeast cell, an insect cell or a mammalian cell; Preferably, the host cell is a mammalian cell, and the mammalian cell is provided as a host cell which is a HEK293 cell, a CHO cell or an NS0 cell.

[0084] The present invention further provides a drug comprising an anti-TSLP monoclonal antibody or an antigen-binding fragment thereof defined in any one of the above embodiments.

[0085] The present invention further provides use of the above-mentioned anti-TSLP monoclonal antibody or antigen-binding fragment thereof in the manufacture of a therapeutic agent for immune diseases or cancer.

[0086] The present invention provides a method for treating or preventing a TSLP-mediated disease, comprising administering a therapeutically effective amount of an anti-TSLP monoclonal antibody to an individual in need thereof, wherein the disease comprises an immune disease or cancer. Preferably, the immune disease includes, but is not limited to, asthma, chronic obstructive pulmonary disease, chronic eosinophilic pneumonia, idiopathic pulmonary fibrosis, and allergic dermatitis; the asthma includes severe asthma, eosinophilic or non-eosinophilic asthma, and hypoeosinophilic asthma.

[0087] Preferably, the cancer includes, but is not limited to, pancreatic cancer, non-small cell lung cancer, melanoma, prostate cancer, renal cancer, colorectal cancer or breast cancer.

[0088] Example 15: Binding experiment of humanized antibody molecule and TSLP TSLP-His is coated with a carbonate buffer solution of pH 9.6, 200ng / well / 100μl, and coated overnight at 4℃. After washing five times with 300μl / well PBST, add 1% BSA-PBST and close at 37℃ for 1h, and add humanized antibodies HA-I, HA-II, HA-III, HA-IV, chimeric antibody CA-I prepared in Example 9, and control antibody at different dilutions. The starting maximum concentration of the six antibodies is 5μg / ml, and each antibody is diluted 5-fold, making a total of 8 steps for each antibody, and incubated at 37℃ for 1h. After washing five times with 300μl / well PBST, add Goat Anti Human IgG-HRP (purchased from Beijing Zhongsugi Jinqiao Biotechnology Co., Ltd., product number: ZB-2304) diluted 1:5000 with 1% BSA-PBST, and incubated at 37℃ for 1h. Develop with TMB color development kit, 100 μl / well, 5 min at room temperature, and terminate with 2M H2SO4. Read at 450 nm / 630 nm on a microplate reader and obtain the corresponding EC 50 The value is calculated as follows:

[0089] [Table 7]

[0090] According to the above data, experimental results, and as shown in Figure 8, all four different humanized antibody molecules can bind to TSLP. 50 All of the values ​​were clearly lower than those of the control antibody. This proves that the monoclonal antibodies provided by the present invention have strong binding ability and high affinity to TSLP. In addition, as is clear from FIG. 8 and the above data, among the four different monoclonal antibodies, the EC value of HA-I was significantly higher than that of the control antibody. 50 This proves that HA-I has the best binding ability and highest affinity with TSLP. At the same time, the EC 50 The values ​​were similar to those of the chimeric antibody CA-I, demonstrating that the humanized HA-I maintains the high affinity for TSLP of the mouse-derived parent antibody MA-I.

[0091] Example 16: Competitive inhibition experiment between humanized antibody and control antibody TSLP-His was coated with carbonate buffer (pH 9.6) at 100ng / well / 100μl, and coated overnight at 4℃. After washing 5 times with 300μl / well of PBST, the plate was blocked with 1% BSA-PBST at 37℃ for 1h, and HA-I, HA-II, HA-III, HA-IV, and chimeric antibody CA-I diluted to 4μg / ml with 1% BSA-PBST were added at 50μl / well, followed by the addition of control antibodies at different dilutions at 50μl / well. The initial maximum concentration of the control antibodies was 400μg / ml, and each was diluted 3-fold in a total of 11 steps, and incubated at 37℃ for 2h. After washing five times with 300 μl / well PBST, Anti-Human IgG1-HRP (purchased from Sigma, product number: SAB4200768) diluted 1:5000 with 1% BSA-PBST was added and incubated at 37°C for 1 h. Color was developed with TMB color development kit, 100 μl / well at room temperature for 10 min, and then 2M H2SO4 was added to terminate the color development. The values ​​were read at 450 nm / 630 nm on a microplate reader, and the corresponding IC50 The value is calculated as follows:

[0092] [Table 8]

[0093] As shown in the above data and in Figure 9, the four different humanized and chimeric antibodies screened can all inhibit the binding of TSLP to the control antibody. At the same time, among the four humanized antibody molecules, the IC 50 The value is the lowest. Therefore, the inhibitory effect of HA-I is the best.

[0094] Example 17: Cross-binding experiments of humanized antibodies with TSLP from different species Human TSLP-His, mouse TSLP-His (purchased from Yiqiao Shenzhou Technology Co., Ltd., product number: 51005-M08H), and monkey TSLP-His (purchased from Kinki Protein Technology Co., Ltd., product number: CR62) are coated with carbonate buffer at pH 9.6, 100ng / well / 100μl, and coated overnight at 4℃. After washing five times with 300μl / well of PBST, add 1% BSA-PBST and close at 37℃ for 1h, and add humanized antibodies HA-I, HA-II, HA-III, and HA-IV at different dilutions. The starting maximum concentration of the four humanized antibodies is 16μg / ml, and each is diluted 4-fold, with a total of 8 dilutions for each antibody, and incubated at 37℃ for 1h. After washing five times with 300 μl / well PBST, Goat Anti Human IgG-HRP diluted 1:5000 in 1% BSA-PBST was added and incubated at 37°C for 1 h. Develop with TMB color development kit, 100 μl / well at room temperature for 5 min, and terminate with 2M H2SO4. Read the values ​​at 450 nm / 630 nm on a microplate reader and obtain the corresponding EC 50 The value is calculated as follows:

[0095] [Table 9]

[0096] As shown in the above data and in Figure 10, all of the four different humanized antibodies screened could bind to human TSLP and cynomolgus TSLP, but did not bind to mouse TSLP. Furthermore, among these four humanized antibody molecules, the EC of HA-I with human TSLP and cynomolgus TSLP was 50 The lowest value proves the strong binding ability of HA-I, allowing the study of pharmacological toxicity and evaluation of safety in the experimental animal model of cynomolgus monkeys.

[0097] Example 18: Experiment to inhibit the binding of TSLP to cell surface receptors by anti-TSLP monoclonal antibodies The BaF / 3-TSLPR engineered cell line was digested and counted, and the cells were diluted to 1 × 10 in sample diluent (containing 90% IMDM, 10% FBS, and 300 μg / ml Hygromycin). 6cells / ml and added to a 96-well plate at 100 μl / well. Each of the humanized antibodies HA-I, HA-II, HA-III, HA-IV and the control antibody is diluted with sample diluent to an initial concentration of 200 μg / ml, and serially diluted 3-fold for a total of 10 steps. Each of the diluted humanized antibodies HA-I, HA-II, HA-III, HA-IV and the control antibody is added to a 96-well plate containing 100 μl of BaF / 3-TSLPR cells at 50 μl / well. The antigen TSLP is diluted with sample diluent to 8 μg / ml and added to the above well plate containing BaF / 3-TSLPR cells, humanized antibody and control antibody at 50 μl / well. After mixing gently, the 96-well plate is incubated at 4°C for 1 h. After incubation, the plate is centrifuged at 3000 rpm to discard the supernatant and collect the cell precipitate. Add 100μl / well of pre-diluted GoatAntiHuman IgG-Fc antibody (purchased from SouthernBiotech, product number: 2048-30) to the plate, mix evenly with the cell precipitate in each well, and culture for 1h at 4℃. After the culture is completed, add 100μl of PBS buffer per well to wash the cells, centrifuge at 3000rpm to discard the supernatant, and add 100μl of PBS buffer per well to resuspend the cell precipitate, and perform measurement by flow cytometer. Collect data and obtain the corresponding IC 50 The value is calculated as follows:

[0098] [Table 10]

[0099] As shown in the data above and in Figure 11, the four different humanized antibodies and the control antibody screened can all compete with TSLP to bind to the cell surface receptor TSLPR. Among the four humanized antibodies, the IC 50 The value was the lowest and was superior to the control antibody, demonstrating that HA-I has a good inhibitory effect on the binding of TSLP to its receptor at the cellular level.

[0100] Example 19: Detection of biological activity of anti-TSLP monoclonal antibody (reporter gene method) BaF / 3 (mouse-derived B cells, purchased from Cell Resource Center of Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, product code: 3111C0001CCC000095) cells expressing TSLPR, IL-7Rα, and STAT5-Luc were digested and counted, and the cells were diluted to 1 × 10 in sample diluent (containing 90% IMDM, 10% FBS, 300 μg / ml Hygromycin, 0.5 μg / ml Puromycin, and 600 μg / ml Geneticin). 6 The cells were diluted to 160 ng / ml, and TSLP-RAS-His antigen was added to the cells to a concentration of 160 ng / ml. After gentle mixing, the cell solution was added to a 96-well plate at 50 μl / well. Each of the humanized antibodies HA-I, HA-II, HA-III, HA-IV, and the control antibody was diluted with sample diluent to an initial concentration of 15 μg / ml, and a 3-fold serial dilution was performed, for a total of 8 steps, with two duplicate wells for each sample concentration. Each of the diluted HA-I, HA-II, HA-III, HA-IV, and the control antibody was added to the 96-well plate containing 50 μl of the cell mixture, and after gentle mixing, the 96-well plate was placed in a cell incubator and incubated for 5 h under the incubation conditions of 37°C and 5% CO2. After 5 hours, the 96-well plate was removed and centrifuged at 3000 rpm / min for 5 minutes. The solution was then shaken off and discarded. Glo Lysis Buffer (purchased from Promega, product number: E2661) was added at 50 μl / well and the cells were lysed at room temperature for 5 minutes. The cell plate was gently tapped to mix the cell lysate uniformly. The cell lysate was transferred to a 384-well plate at 10 μl / well and mixed with an equal amount of Bright-Gol. TM Add Luciferase Assay System, react at room temperature for 2-15 minutes, read the fluorescence value with a microplate reader, and calculate the corresponding IC 50 The value is calculated as follows:

[0101] [Table 11]

[0102] As shown in the above data and FIG. 12, all of the four different humanized antibodies and control antibodies screened can bind to TSLP, and exert their effects by competitively inhibiting the binding of TSLP to the receptor complex, thereby blocking the intracellular signal pathway. The construction of the engineered cell line BaF / 3-TSLPR-IL7Rα-STAT5-Luc can simulate the proliferation response of human hypertrophic cells under the action of TSLP. TSLP stimulates and enhances the expression of intracellular proliferation signal (STAT5-Luc) by binding to the TSLPR and IL7Rα receptor on the cell surface. These four humanized antibody molecules can effectively inhibit the binding action of TSLP to the cell surface receptor, and further inhibit the generation and development of intracellular proliferation signal. In addition, among these four humanized antibody molecules, the IC of HA-I was significantly higher than that of HA-I. 50 The value was the lowest and was obviously superior to the control antibody, proving that HA-I can inhibit the binding of TSLP to its receptor at the cellular level and has the most effective cell proliferation inhibitory effect.

[0103] Example 20: Inhibition of chemokine release from TSLP-induced mDC cells by anti-TSLP monoclonal antibodies PBMC cells were reactivated and mature DC cells were obtained by sorting using a kit. The cells were then diluted to a density of 4 × 10 in sample diluent (containing 90% 1640 and 10% FBS). 5The cell suspension was adjusted to 1000 cells / mL and 50 μL / well of the cell suspension was added to a 96-well plate. Each of the humanized antibodies HA-I, HA-II, HA-III, HA-IV and the control antibody was diluted with sample diluent to an initial concentration of 80 ng / mL, and then serially diluted 3-fold for a total of 8 levels, with two duplicate wells for each sample concentration, and added to the 96-well plate containing mature DC cells at 25 μL / well. TSLP protein was diluted to 80 ng / mL with sample diluent and added to the 96-well plate containing mature DC cells, humanized antibodies and control antibodies at 25 μL / well. After gentle mixing, the 96-well plate was placed in a CO2 incubator at 37°C and incubated overnight, and after about 24 hours, the supernatant was taken and added at 50 μL / well. The TARC test was performed according to the instructions of the human TARC ELISA kit (purchased from Dacowei Biotechnology Co., Ltd., product number: 1117542). First, dilute the supernatant 3-fold with the diluent provided in the kit and mix uniformly. Add the diluted supernatant and standard to the sample wells at 100 μl / well and incubate at room temperature for 2 hours. After incubation, wash the well plate three times with washing solution. Add the biotinylated antibody dilution at 100 μl / well and incubate at room temperature for 2 hours. After incubation, wash the well plate three times with washing solution. Add the Streptavidin-HRP working solution at 100 μl / well and incubate at room temperature for 20 minutes. After incubation, wash the well plate three times with washing solution. Add the TMB color development solution at 100 μl / well and incubate at room temperature in the dark for approximately 15 minutes. Stop the color development with 100 μl / well of stop solution. Read the OD value at 450 nm on a microplate reader and obtain the corresponding IC 50 The value is calculated as follows:

[0104] [Table 12]

[0105] As shown in the above data and in Figure 13, all of the four different humanized antibodies and the control antibody screened can inhibit the release of the chemokine TARC from TSLP-activated mDC cells. In addition, among these four humanized antibody molecules, the IC 50 This was the lowest value and was clearly superior to the control antibody, demonstrating that HA-I can effectively inhibit the activation effect of TSLP on mDCs at the cellular level and has the most excellent inhibitory effect.

[0106] Example 21: Evaluation of thermal stability of anti-TSLP monoclonal antibody HA-I The anti-TSLP monoclonal antibody HA-I is exchanged into a PBS buffer system by ultrafiltration, centrifuged at 12000 rpm and 4°C for 5 min, and the thermal stability of the anti-TSLP monoclonal antibody HA-I is evaluated using a multifunctional protein thermal stability analysis system (purchased from Unchained Labs). The temperature-dependent change in protein intrinsic fluorescence (heating from 25°C to 95°C at a heating rate of 0.3°C / min) is monitored to detect protein structural changes, thereby determining the protein melting temperature Tm and evaluating the stability of the protein structure. When aggregation of the sample occurs, interference of scattered light waves occurs, and the scattered light signal increases. The colloidal stability of the protein (characterized by Tagg) is measured by static light scattering. As a result, see the table below and Figure 14.

[0107] [Table 13]

[0108] As shown in the above table and FIG. 14, the anti-TSLP monoclonal antibody HA-I has a temperature of 71.7° C. and an average Tagg of 83.0° C., showing good structural and colloidal stability.

[0109] Example 22: Toxicity study of anti-TSLP monoclonal antibody administered subcutaneously to cynomolgus monkeys for 4 weeks The purpose of the study was to subcutaneously inject anti-TSLP monoclonal antibody into cynomolgus monkeys once a week and observe the toxic reactions after four consecutive weeks of administration.

[0110] (1) Experimental product information: anti-TSLP monoclonal antibody HA-I prepared into injection solution (auxiliary materials include histidine, histidine hydrochloride, sorbitol, polysorbate 80); Control product information: The buffer solution of anti-TSLP monoclonal antibody HA-I (containing histidine, histidine hydrochloride, sorbitol, and polysorbate 80, and not containing the drug component anti-TSLP monoclonal antibody HA-I, and other components of the injection solution are the same) is used as the control; (2) Provided by: Beijing Oriental Baitai Biotechnology Co., Ltd. (3) Experimental animals: Type and Breed: Cynomolgus monkey; Age: 2.5-5 years old; Weight: 2-5kg; Gender: female, male; Number of animals: 4 each of sexes, 8 in total;

[0111] [Table 14]

[0112] Administered via subcutaneous injection, the first dose is designated as D1, followed by weekly doses for 4 consecutive weeks, for a total of 5 doses; The parameters evaluated in this study are clinical symptoms, body weight, food intake, body temperature, associated safety pharmacological indicators, electrocardiogram, blood pressure, ophthalmological examination, clinical pathology (blood cell count, coagulation function, blood biochemistry analysis, urine analysis), immunological indicators (immune cell phenotype, cellular factors, immunoglobulins, complement), anti-drug antibodies, and toxicokinetics.

[0113] Experimental results: During the experiment, clinical observations, body weight, body temperature, electrocardiogram parameters, blood cell counts, blood biochemistry, urine tests, and T lymphocyte subpopulation measurements were performed on the animals in each group, and animals in groups 2 to 4 were dissected for general observation. As a result, no obvious abnormal changes or obvious irregular abnormal changes were found in each index.

[0114] In addition, in female animals in the 300 mg / kg dose group, FIB increased before the second dose (D8) and the day after the third dose (D16), and returned to normal the day after the final dose (D30), and no abnormalities were observed in the remaining animals. 1 to 2 hours after the first dose (D1), IL-6 increased in male animals in the 30 mg / kg dose group, whereas IL-10 increased in female animals in the 300 mg / kg dose group, and both returned to normal the next day. On the day after the first dose (D2), IL-6 increased in both male and female animals in the 300 mg / kg dose group, and returned to normal before D8 dose. Before the second dose (D8), IL-10 also increased in female animals in the 300 mg / kg dose group, and returned to normal on D29, and no other obvious abnormal changes were observed.

[0115] No ADA was detected in any of the animals in either group during the experiment.

[0116] As shown by the toxicokinetic results, anti-TSLP monoclonal antibody HA-I was administered subcutaneously to cynomolgus monkeys at doses of 30, 100, and 300 mg / kg, respectively. After the first and fourth administration, the blood drug concentration and exposure increased with increasing dose, and no obvious gender differences were observed in the main toxicokinetic parameters. After weekly administration for four consecutive weeks, EB070 was slightly accumulated in the cynomolgus monkeys (accumulation factor 1.49-2.71).

[0117] Example 23: Toxicity study of anti-TSLP monoclonal antibody administered subcutaneously to cynomolgus monkeys for 13 weeks In addition to the objectives of Example 21, the objective of this experimental study is to evaluate the toxic reactions and toxicokinetic status after 13 weeks of repeated subcutaneous administration of anti-TSLP monoclonal antibody once a week to cynomolgus monkeys by injection, as well as the status of recovery from toxicity 6 weeks after discontinuation of the drug.

[0118] (1) Experimental product information: anti-TSLP monoclonal antibody HA-I prepared into injection solution (auxiliary materials include histidine, histidine hydrochloride, sorbitol, polysorbate 80); Control product information: The buffer solution of anti-TSLP monoclonal antibody HA-I (containing histidine, histidine hydrochloride, sorbitol, and polysorbate 80, and not containing the drug component anti-TSLP monoclonal antibody HA-I, and other components of the injection solution are the same) is used as the control; (2) Provided by: Beijing Oriental Baitai Biotechnology Co., Ltd. (3) Experimental animals: Type and Breed: Cynomolgus monkey; Age: 3-5 years old; Weight: 2-5kg; Gender: female, male; Number of animals: 20 males and 20 females, total 40;

[0119] [Table 15]

[0120] The drug is administered by subcutaneous injection, the first dose is designated as D1, followed by one dose per week for 13 consecutive weeks, for a total of 14 doses; the parameters evaluated in this experiment are clinical symptom observation, body weight, food intake, body temperature, associated safety pharmacological index tests, electrocardiogram, blood pressure, ophthalmological examination, clinical pathological examination (blood cell count, coagulation function, blood biochemistry analysis, urine analysis), immunological index (immune cell phenotype, cellular factors, immunoglobulins, complement), antidrug antibodies, and toxicokinetics.

[0121] As is clear from the results of preliminary experiments, after repeated subcutaneous administration of anti-TSLP monoclonal antibody HA-I to cynomolgus monkeys, no obvious abnormalities were found in the animal clinical observations, body weight, body temperature, ophthalmic examinations, or gross necropsy.

[0122] The present invention is not limited to the above-mentioned preferred embodiment. Anyone can obtain various other forms of products under the teaching of the present invention. However, any changes in shape or structure are included in the scope of protection of the present invention as long as they are the same or similar technical solutions as those in the present application.

Claims

1. An anti-TSLP monoclonal antibody or an antigen-binding fragment thereof, a heavy chain variable region comprising three heavy chain complementarity determining regions designated HCDR1, HCDR2 and HCDR3, respectively; and a light chain variable region comprising three light chain complementarity determining regions designated LCDR1, LCDR2 and LCDR3, respectively; The monoclonal antibody or antigen-binding fragment thereof may be A-I: the heavy chain complementarity determining region HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1, the heavy chain complementarity determining region HCDR2 comprises the amino acid sequence shown in SEQ ID NO:2, the heavy chain complementarity determining region HCDR3 comprises the amino acid sequence shown in SEQ ID NO:3, the light chain complementarity determining region LCDR1 comprises the amino acid sequence shown in SEQ ID NO:4, the light chain complementarity determining region LCDR2 comprises the amino acid sequence shown in SEQ ID NO:5, and the light chain complementarity determining region LCDR3 comprises the amino acid sequence shown in SEQ ID NO:6; A-II: the heavy chain complementarity determining region HCDR1 comprises the amino acid sequence shown in SEQ ID NO:7, the heavy chain complementarity determining region HCDR2 comprises the amino acid sequence shown in SEQ ID NO:8, the heavy chain complementarity determining region HCDR3 comprises the amino acid sequence shown in SEQ ID NO:9, the light chain complementarity determining region LCDR1 comprises the amino acid sequence shown in SEQ ID NO:4, the light chain complementarity determining region LCDR2 comprises the amino acid sequence shown in SEQ ID NO:10, and the light chain complementarity determining region LCDR3 comprises the amino acid sequence shown in SEQ ID NO:6; A-III: the heavy chain complementarity determining region HCDR1 comprises the amino acid sequence shown in SEQ ID NO:1, the heavy chain complementarity determining region HCDR2 comprises the amino acid sequence shown in SEQ ID NO:11, the heavy chain complementarity determining region HCDR3 comprises the amino acid sequence shown in SEQ ID NO:3, the light chain complementarity determining region LCDR1 comprises the amino acid sequence shown in SEQ ID NO:12, the light chain complementarity determining region LCDR2 comprises the amino acid sequence shown in SEQ ID NO:13, and the light chain complementarity determining region LCDR3 comprises the amino acid sequence shown in SEQ ID NO:14; and A-IV: An anti-TSLP monoclonal antibody or an antigen-binding fragment thereof, characterized in that the anti-TSLP monoclonal antibody is any one of the following: the heavy chain complementarity determining region HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 1; the heavy chain complementarity determining region HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 11; the heavy chain complementarity determining region HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 3; the light chain complementarity determining region LCDR1 comprises the amino acid sequence shown in SEQ ID NO: 12; the light chain complementarity determining region LCDR2 comprises the amino acid sequence shown in SEQ ID NO: 15; and the light chain complementarity determining region LCDR3 comprises the amino acid sequence shown in SEQ ID NO:

16.

2. The monoclonal antibody or antigen-binding fragment thereof is a mouse-derived antibody molecule, and the mouse-derived antibody molecule is MA-I: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:17 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:18; MA-II: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:19 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:20; MA-III: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:21 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:22; and MA-IV: the heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO:23, and the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO:24; The anti-TSLP monoclonal antibody or antigen-binding fragment thereof according to claim 1, characterized in that the mouse-derived antibody molecule is MA-I.

3. The mouse-derived antibody molecule further comprises a mouse-derived antibody heavy chain constant region selected from mouse IgG1, IgG2a, IgG2b, or IgG3 heavy chain constant regions, and a mouse-derived antibody light chain constant region; provided that the amino acid sequence of the IgG1 type heavy chain constant region is as shown in SEQ ID NO: 26, the amino acid sequence of the IgG2a type heavy chain constant region is as shown in SEQ ID NO: 27, the amino acid sequence of the IgG2b type heavy chain constant region is as shown in SEQ ID NO: 28, and the amino acid sequence of the IgG3 type heavy chain constant region is as shown in SEQ ID NO: 29; and the mouse-derived antibody light chain constant region is selected from mouse C k a light chain constant region of the type Ib-IIb type, and the amino acid sequence thereof is as set forth in SEQ ID NO:25; Preferably, the mouse-derived antibody molecule comprises a mouse IgG1 heavy chain constant region and a mouse C k and a light chain constant region of the type Ib of the monoclonal antibody or antigen-binding fragment thereof.

4. The anti-TSLP monoclonal antibody or antigen-binding fragment thereof according to claim 2, characterized in that the monoclonal antibody or antigen-binding fragment thereof is a chimeric antibody molecule, and the chimeric antibody molecule comprises a heavy chain variable region of the mouse-derived antibody molecule, a light chain variable region of the mouse-derived antibody molecule, and a human-derived antibody constant region.

5. The monoclonal antibody or antigen-binding fragment thereof is a humanized antibody molecule, and the humanized antibody molecule includes HA-I: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:34 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:35; HA-II: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:34 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:36; HA-III: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:37 and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:38; and HA-IV: the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:37, and the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO:36; The anti-TSLP monoclonal antibody or antigen-binding fragment thereof according to claim 1, characterized in that the humanized antibody molecule is preferably HA-I.

6. The anti-TSLP monoclonal antibody or antigen-binding fragment thereof of claim 5, wherein the humanized antibody molecule further comprises a human-derived antibody constant region.

7. The humanized antibody molecule is a full-length antibody or an antibody fragment, and the humanized antibody molecule is a Fab, F(ab) 2 7. The anti-TSLP monoclonal antibody or antigen-binding fragment thereof according to claim 5 or 6, characterized in that it comprises one or a combination of several of Fv, ScFv or ScFv.

8. The human-derived antibody constant region comprises a human-derived antibody heavy chain constant region selected from human IgG1, IgG2, or IgG4 heavy chain constant regions, and a human-derived antibody light chain constant region, the amino acid sequence of the IgG1 heavy chain constant region being as shown in SEQ ID NO: 30, the amino acid sequence of the IgG2 heavy chain constant region being as shown in SEQ ID NO: 31, and the amino acid sequence of the IgG4 heavy chain constant region being as shown in SEQ ID NO: 32, and the human-derived antibody light chain constant region being a human C k a light chain constant region of the type IHVIII-IIIHVIII-IIIHVIII type, and the amino acid sequence thereof is as set forth in SEQ ID NO:33; Preferably, the human-derived antibody constant region is a heavy chain constant region of human IgG1 type and a human C k and a light chain constant region of the type Ib of the monoclonal antibody or antigen-binding fragment thereof.

9. A protein comprising an anti-TSLP monoclonal antibody or an antigen-binding fragment thereof according to any one of claims 1 to 8.

10. A polynucleotide molecule encoding an anti-TSLP monoclonal antibody or an antigen-binding fragment thereof according to any one of claims 1 to 8.

11. A recombinant DNA expression vector comprising the polynucleotide molecule of claim 10.

12. A host cell transfected with the recombinant DNA expression vector of claim 11, The host cell comprises a prokaryotic cell, a yeast cell, an insect cell or a mammalian cell; Preferably, the host cell is a mammalian cell, the mammalian cell being a HEK293 cell, a CHO cell or an NSO cell.

13. A drug comprising an anti-TSLP monoclonal antibody or an antigen-binding fragment thereof according to any one of claims 1 to 8.

14. Use of the anti-TSLP monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 8 in the manufacture of a therapeutic agent for immune diseases or a therapeutic agent for cancer; Preferably, said immune disease comprises asthma, chronic obstructive pulmonary disease, chronic eosinophilic pneumonia, idiopathic pulmonary fibrosis, allergic dermatitis; said asthma comprises severe asthma, eosinophilic or non-eosinophilic asthma, hypoeosinophilic asthma; Preferably, the cancer comprises pancreatic cancer, non-small cell lung cancer, melanoma, prostate cancer, renal cancer, colorectal cancer or breast cancer.

15. 1. A method for treating or preventing a TSLP-mediated disease, comprising:

9. A method for treating a cancer comprising administering to an individual in need thereof a therapeutically effective amount of an anti-TSLP monoclonal antibody according to any one of claims 1 to 8, wherein the disease comprises an immune disease or cancer; The immune disorders include asthma, chronic obstructive pulmonary disease, chronic eosinophilic pneumonia, idiopathic pulmonary fibrosis, and allergic dermatitis; the asthma includes severe asthma, eosinophilic or non-eosinophilic asthma, and hypoeosinophilic asthma; The method, wherein the cancer comprises pancreatic cancer, non-small cell lung cancer, melanoma, prostate cancer, renal cancer, colorectal cancer or breast cancer.

Citation Information

Patent Citations

  • Thymic Stromal Lymphopoietic Factor (tslp) Binding Antibodies and Methods of Using the Antibodies

    JP2018533911A

  • Antibodies binding TSLP and uses thereof

    WO2021043221A1

  • Development and application of therapeutic agents for TSLP-related diseases

    WO2021104053A1

  • Anti-human-TSLP antibody and use thereof

    WO2021155634A1